Abbreviations: ATG = anti-thymocyte globulin; CI = confidence interval; CMV = cytomegalovirus; CY = cyclophosphamide; FLU = fludarabine; GF = graft failure; GVHD = graft-versus-host disease; MEL = melphalan; TBI = total body irradiation.
Currently, UBMT is recommended for the treatment of patients with severe aplastic anemia (SAA) who do not have HLA-matched siblings and do not respond to immunosuppressive therapy. 1 In contrast, early studies demonstrated that the use of UCBT for SAA was associated with a higher incidence of graft failure and poor outcomes. 2 Because UCBT is indicated only for patients who lack a suitable UBMT donor, there is limited experience and the optimal conditioning regimen is unknown.
We retrospectively analyzed the outcomes of 27 Japanese children with acquired AA who received UCBT between 1998 and 2013. Data collected as of October 2014 were analyzed. Ten patients were already included in the previous study. 3 The data management committee of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) approved this study. Patients' characteristics and transplant outcomes are summarized in Table 1 and Online Supplementary Table S1 . The HLA disparities for both the GVH and host-versus-graft directions are also shown in Supplementary Table S1 . The median total nucleated cell number and CD34-positive cell number at cryopreservation were 3.99 × 10 7 /kg (range, 0.09-16.11) and 1.31 × 10 5 /kg (range, 0.39-6.17), respectively.
The conditioning regimens varied according to individual institutes. Seven patients received fludarabine (FLU: 120-175 mg/m 2 )+cyclophosphamide (CY: 50-100 mg/kg)+total body irradiation (TBI: 2-6 Gy). Three received Flu+CY+TBI with rabbit ATG (Thymoglobulin: 5-10 mg/kg). Four received FLU+melphalan (MEL: 80-120 mg/m 2 )+TBI. Six received FLU+CY+ATG. The remaining seven received other conditioning regimens. As for GVH disease (GVHD) prophylaxis, regimens based on cyclosporine (n = 9) or tacrolimus (n = 17) were used.
Neutrophil recovery (40.5 × 10 9 /L) was observed in 19 patients and the median time to engraftment was 20 days. Platelet recovery (50 × 10 9 /L) was observed in 17 patients and the median time to recovery was 50 days. Primary graft failure (GF) was observed in eight patients. One patient experienced secondary GF, and thus sustained engraftment was observed in 18 patients ( Table 1) . We screened for anti-HLA antibodies in eight patients but none of them were positive. Cumulative incidences (CI) of Grade II-IV acute GVHD at day 100 and chronic GVHD at 3-year were 23.1% ( range: 9.0-40.7) and 12.0% (range: 2.8-28.3), respectively (Supplementary Figure S1) . The median follow-up period was 18 months after UCBT; 19 of 27 patients were alive at the end of follow-up. The causes of death were bacterial/fungal infections (n = 3), veno-occlusive disease (n = 2), Epstein-Barr virus lymphoproliferative disorder (n = 1), second malignancy (n = 1), and secondary GF (n = 1).
The 5-year overall survival (OS) and failure-free survival (FFS) of all patients were 69.5% (range: 48.1-83.5) and 59.3% (range: 38.6-75.0), respectively. The definition of treatment failure included death from all causes, GF and second malignancy. Of 17 patients who received UCBT after 2006, the 5-year OS was excellent, at 93.8% (range: 81.6-100%). The results of univariate analysis of factors influencing OS and FFS are shown in Supplementary Table S2 . The conditioning regimens that included TBI resulted in a significantly better FFS (hazard ratio: 0.18; range: 0.05-0.62; P = 0.0065). On the other hand, the conditioning regimens that included ATG exhibited a significantly worse FFS (hazard ratio: 11.64; range: 1.48-91.44). To confirm the combined effect of these favorable factors, we divided the patients into 2 groups according to the conditioning regimens. The 5-year OS and FFS of the 11 patients who received FLU+CY/MEL+TBI were both 100%, and were significantly better than those of the 16 patients who were conditioned with other regimens (OS: 48.6%; range: 22.9-70.3; P =0.007; FFS: 31.2%; range; 11.4-53.6; Po0.001) (Figure 1) . The clinical characteristics of the 11 patients who received FLU+CY/MEL+TBI and the other 16 patients are summarized in Online Supplementary Tables S3 and S4. ATG is widely used to decrease the incidence of GF, including both acute and chronic GVHD, in the conditioning regimens of hematopoietic stem cell transplantation (HSCT) for AA. 4 Our previous study of UBMT for SAA revealed that non-ATG regimens were associated with a significantly higher incidence of grade III/IV acute GVHD and decreased 5-year OS. 5 Currently, in both Europe and the United States the recommended regimen for UBMT in SAA is FLU+CY+ATG+low-dose TBI. 6, 7 This is identical to the most popular conditioning regimen for UCBT. 8 In the largest study of this issue to date, the European Group for Blood and Marrow Transplantation (EBMTG) reviewed 71 SAA patients who received UCBT between 1996 and 2009. Although the majority of the patients received reduced-intensity conditioning regimens with ATG, the 3-year OS was only 38 ± 6%, which was far inferior to that of UBMT. In the series, 53 of 67 (79%) patients received ATG regimens. 9 In contrast, in vivo T-cell depletion with ATG has been uncommonly used in UCBT in Japan. Recently, a Japanese group analyzed the outcomes of 69 adult patients with AA who received UCBT between 2002 and 2012. Of 69 patients, 66 (96%) were conditioned with non-ATG regimens. The 3-year OS was fairly good, at 69% (range: 53-81). The large difference between EBMTG and Japanese adult studies has concerned the use of ATG. 10 Unexpectedly, our study revealed that the ATG regimen was an unfavorable factor for both OS and FFS. Only 1 of 12 patients (8.3%) died in the non-ATG group, but 7 of 15 patients (46.7%) died in the ATG group. The incidence of GF also differed markedly between the 2 groups: primary GF developed in 8 of 15 patients (53.3%) in the ATG group but in none of the 12 patients in the non-ATG group. The incidences of grade II-IV acute GVHD and chronic GVHD were comparable between the ATG and non-ATG groups. These findings contrast with the observations in UBMT that ATG has a favorable effect in terms of facilitating engraftment and decreasing the incidence of both acute and chronic GVHD.
It is well known that T cells in the graft, especially, CD8 + T cells, facilitate optimal engraftment in HSCT. Terakura et al.
11 measured the number of CD34 + cells and CD8 + T cells in the UCB unit and evaluated their influence on engraftment. They found that the CD8 + T-cell dose significantly influenced the time to achieve neutrophil engraftment in patients receiving a lower CD34 + cell dose, whereas there was no significant influence in patients receiving a higher CD34 + cell dose. 11 These findings suggest that the detrimental effects of in vivo T-cell depletion with ATG may be observed only in UCBT recipients with a limited number of CD34 + cells in their grafts. On the other hand, in our study we did not observe the favorable effect of ATG in decreasing the incidence of acute and chronic GVHD because of the low baseline incidence of GVHD in the non-ATG group. The EBMTG conducted a multicenter retrospective study to assess the impact of ATG in 661 adult patients with hematologic malignancies who underwent UCBT following reduced-intensity conditioning consisting of FLU+CY +low-dose TBI. In multivariate analysis, the use of ATG was associated with a higher incidence of non-relapse mortality and decreased OS, especially if given too close to graft infusion, leading to the recommendation to avoid the use of ATG in patients receiving UCBT following FLU+CY+low-dose TBI regimens. 12 Because most of the patients received ATG from day-5 to day-2 in our cohort, the close use of ATG to graft infusion might be related high incidence of graft failure. Our results suggest that the use of ATG should also be reconsidered in AA patients receiving UCBT.
Although our study is limited in terms of its retrospective nature and small number of patients, it suggests that FLU+CY/MEL +lower-dose TBI without ATG is potentially an optimal conditioning regimen for UCBT in patients with AA. We believe that the suggested conditioning regimen deserves further evaluation in a large prospective study. 
